Global Dupuytrens Disease Market Size and Trends

The global Dupuytren’s disease market size is valued at US$ 4.3 Bn in 2023 and is expected to reach US$ 5.9 Bn by 2030, growing at a compound annual growth rate (CAGR) of 4.6% from 2023 to 2030.

The market is driven by factors such as increasing geriatric population prone to developing Dupuytren's disease, rising focus on early diagnosis and treatment, and growing number of clinical trials evaluating novel treatment alternatives. Moreover, improving healthcare infrastructure and expanding patient pool indicate promising growth opportunities. However, high cost of surgical procedures remains a major restraint in developing markets.

Important opportunities lie in the development of new drugs targeting the disease's pathological processes. Minimally invasive procedures could also gain favor over extensive hand surgeries due to their advantages of faster recovery times and lower risks of complications. Outpatient care settings are expected to gradually replace hospital-based treatment models. Collaborations between players for developing combination therapies may further expand the available treatment options. Overall, the Dupuytren's disease market prospects appear bright with ongoing research and development activities.

Global Dupuytren’s Disease Market Trends:

Focus on combination therapy: The trend of combination therapy is having a significant impact on the global Dupuytren's disease market. Dupuytren's disease is a progressive fibromatosis condition affecting the hands. Traditional treatments have involved surgery or needle fasciotomy to release or remove fibrous tissues. However, there is now a growing focus on combining these interventions with additional non-surgical therapies to improve outcomes. Surgery or needle fasciotomy with collagenase clostridium histolyticum (CCH) injections have become an increasingly popular treatment approach. CCH works by enzymatically dissolving the collagen in fibrous cords. Using CCH both before and after surgical release of cords allows for better straightening of the affected fingers. According to the Phase III clinical trial results published by the manufacturer in 2021, over 70% of patients achieved successful finger extension compared to around 50% with surgery alone. Combining interventions in this way reduces the need for multiple surgeries and leads to improved hand function.
Shift towards minimally invasive procedures: The trend towards minimally invasive procedures is having a significant influence on the global Dupuytren's disease market. However, over the past decade, there has been a marked shift towards minimally invasive surgical procedures for treating this condition. Minimally invasive procedures, such as needle fasciotomy, collagenase clostridium histolyticum injection, and others, percutaneous release techniques are becoming increasingly popular as they are associated with less post-operative pain, quicker recovery times, and comparable clinical outcomes to open fasciectomy.
Increasing awareness about the disease Increasing awareness about the disease is expected to drive the growth of the market over the forecast period. For instance, in October 2022, Endo International plc, a pharmaceutical company, announced the launch of its new branded video series, Coffee & Cords, which aims to educate people about Dupuytren's contracture (DC), a progressive hand condition that results in the formation of a collagen rope-like cord that pulls fingers toward the palm.
Increasing demand for biosimilars: The increasing demand for biosimilars is having a significant impact on the global Dupuytren's disease market. Biosimilars are biologic medical products that are developed to be similar to an existing approved biologic product, referred to as the reference product. In recent years, there has been tremendous growth in the development and approvals of biosimilars for the treatment of various medical conditions. This rise in biosimilar approvals and availability is influencing treatment patterns for Dupuytren's disease as well. Dupuytren's disease is a progressive fibroproliferative disorder affecting the hand and fingers. Traditionally, surgery was the mainstay of treatment for advanced cases. However, the approval of the first biologic therapy, collagenase clostridium histolyticum (CCH) in 2010 provided an important non-surgical option. CCH received widespread adoption and largely dominated the Dupuytren's disease treatment landscape over the past decade.